KOOL News 1.49 Thermogenesis (KOOL)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Thermogenesis (KOOL) 1.49 $KOOL

Cesca Therapeutics Announces Sales & Marketing Organizational Restructuring and the Appointment of Industry Veteran Tim Lee as Director of International Sales
GlobeNewswire - Wed Apr 16, 8:10AM CDT
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company, today announced the restructuring of its sales, marketing and technical support organization and the appointment of Tim Lee as Director of International Sales. The restructuring is aimed at further strengthening its cord blood business and new point of care and clinical commercial programs by providing more dedicated resource leadership to each discipline.

Cesca Therapeutics Submits pre-IDE Information Package to FDA for Surgwerks(TM) CLI therapy System
GlobeNewswire - Wed Mar 26, 8:00AM CDT
Cesca Therapeutics, Inc. (Nasdaq:KOOL), an autologous cell based regenerative medicine company, announced it has submitted a pre-IDE (Investigational Device Exemption) information package to the U. S. Food and Drug Administration (FDA) for the use of the SurgWerks(TM) CLI Therapy designed to treat no option patients with late stage critical limb ischemia (CLI).

Cesca Therapeutics to Present at Regen Med Investor Day March 26 in New York
GlobeNewswire - Tue Mar 18, 8:00AM CDT
CESCA THERAPEUTICS announced today that Matt Plavan, Chief Executive Officer and Ken Harris, President will present at the 2nd Annual Regen Med Investor Day to be held Wednesday, March 26, 2014 in New York City.

Cesca Therapeutics (KOOL) Research Report Issued By WealthMakers.com
M2 - Mon Mar 17, 10:09AM CDT
March 17, 2014 / M2 PRESSWIRE / WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a new research report today on Cesca Therapeutics (NASDAQ: KOOL). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price of $1.78 and the projected fundamental valuation of $4.25.

Cesca Therapeutics Appoints Dr. Mahendra Rao to Board of Directors
GlobeNewswire - Mon Mar 03, 8:15AM CST
Cesca Therapeutics Inc. (Nasdaq:KOOL), formerly known as ThermoGenesis Corp., today announced that Dr. Mahendra Rao has been appointed to the Company's board of directors effective April 1, 2014. His appointment brings the Company's number of directors to six.

Cesca Therapeutics and Cook Medical Enter Supply Agreement for a Phase 1b Clinical Trial
GlobeNewswire - Mon Feb 24, 8:00AM CST
Cesca Therapeutics Inc. (Nasdaq:KOOL), formerly known as ThermoGenesis Corp., announced today that they have entered a supply agreement with Cook Medical.

5 Stocks Ready to Skyrocket Higher
at The Street - Wed Feb 19, 1:14PM CST
These stocks are setting up to explode to the upside.

Cesca Therapeutics Inc., Formerly ThermoGenesis Corp., Closes Merger With TotipotentRX Corporation and Changes Name
GlobeNewswire - Wed Feb 19, 6:30AM CST
Cesca Therapeutics Inc. (f/n/a ThermoGenesis Corp.) ("Company" (Nasdaq:KOOL) today announced that it consummated the merger with TotipotentRX Corporation ("TotipotentRX" for approximately 12,490,800 shares of the Company's common stock, as contemplated by the previously announced Agreement and Plan of Reorganization (the "Merger Agreement".

ThermoGenesis Corp. Reports Second Quarter Fiscal 2014 Results
GlobeNewswire - Fri Feb 14, 3:00PM CST
ThermoGenesis Corp. (Nasdaq:KOOL) ("ThermoGenesis", a leading supplier of enabling technologies for the processing and storage of stem cells and other biological tissues, today reported financial results for the second quarter of fiscal 2014.

ThermoGenesis Corp. Stockholders Approve Acquisition of TotipotentRX
GlobeNewswire - Thu Feb 13, 12:50PM CST
ThermoGenesis Corp. (Nasdaq:KOOL) ("ThermoGenesis", a leading supplier of enabling technologies for the processing and storage of stem cells and other biological tissues, reported today that it received stockholder approval at a special meeting of the stockholders for the acquisition of TotipotentRX through a merger into ThermoGenesis. Incident to the acquisition, ThermoGenesis will also change its corporate name to Cesca Therapeutics Inc., which stands for Clinical Excellence in Stem Cell Applications.

ThermoGenesis Corp. to Announce Second Quarter Fiscal 2014 Results on February 14, 2014
GlobeNewswire - Tue Feb 11, 8:00AM CST
ThermoGenesis Corp. (Nasdaq:KOOL), a leading supplier of innovative products that process and store adult stem cells, announced today it will report financial results for the fiscal second quarter ended December 31, 2013, on Friday, February 14, 2014.

DeNA Reports Third Quarter, Fiscal Year 2013 Financial Results
GlobeNewswire - Wed Feb 05, 12:04AM CST
DeNA Co., Ltd. (Tokyo:2432), the global leader in mobile Internet services, today announced its financial results for the quarter ended December 31, 2013. DeNA reported quarterly revenue of 41.7 billion yen (408 million* USD), 20 percent lower than the same quarter last year, and operating profit of 11.4 billion yen (112 million* USD), 42 percent lower than the same quarter of the previous year.

TotipotentRX and ThermoGenesis Achieve Bone Marrow Stem Cell Transplant Milestone
GlobeNewswire - Mon Feb 03, 8:20AM CST
ThermoGenesis Corp. (Nasdaq:KOOL) a cellular therapy medical device company and TotipotentRX Corporation, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular and orthopedic disease, announced the TotiPotentRX cellular therapy clinical team in partnership with Fortis Healthcare, Gurgaon (New Delhi) has achieved its 20 pediatric bone marrow transplant (BMT). This haploidentical BMT was performed from a mother as a donor for a 10 year old child suffering from combined immunodeficiency due to a DOCK-8 gene mutation. The Fortis Centre has so far performed 15 allogenetic BMT including five haploidentical and one double unrelated cord blood transplants, and 5 autologous transplants. This transplant was completed on February 1, 2014 at the Pediatric Hematology and Bone Marrow Transplant department led by Dr. Satya Yadav, M.D., Head of the Department for Pediatric Hematology and Bone Marrow Transplant, and with scientific and laboratory support by the TotipotentRX's cell therapy GMP laboratory facility. This 20 transplant is a significant milestone in the pursuit of developing the new FMRI BMT program into one of the leading stem cell transplant centers in Asia.

ThermoGenesis Corp. Raises $6.67 Million in Private Placement Financing
GlobeNewswire - Mon Jan 27, 8:00AM CST
ThermoGenesis Corp. (Nasdaq:KOOL) today announced that it has entered into definitive agreements with institutional investors in connection with a private placement of common stock and warrants to purchase common stock. Upon the closing of this financing, ThermoGenesis will receive gross proceeds of approximately $6.67 million resulting from the issuance and sale of approximately 3.33 million shares of common stock at a price per share of $2.00. The purchasers will also receive warrants to purchase up to approximately 1.66 million shares of common stock at an exercise price of $2.81 per share. The warrants are non-exercisable for six months after the closing of the financing and have a term of 5 years.

Most active Nasdaq-traded stocks
AP - Wed Jan 22, 5:03PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:

Nasdaq stocks posting largest volume increases
AP - Wed Jan 22, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:

TotipotentRX Corporation and ThermoGenesis Corp. Report Statistically Significant Phase Ib Clinical Trial Results in Critical Limb Ischemia
GlobeNewswire - Tue Jan 21, 8:00AM CST
ThermoGenesis Corp. (Nasdaq:KOOL) a cellular therapy medical device company and TotipotentRX Corporation, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular and orthopedic disease announce their co-sponsored Phase Ib clinical trial safety and efficacy results treating no-option patients suffering from critical limb ischemia with Totipotent's CLIRST (Critical Limb Ischemia Rapid Stem cell Therapy) treatment. The companies will host a joint conference call to review the study results in detail on Monday, January 27, 2014 at 2:00pm Pacific (5:00pm Eastern).

ThermoGenesis Signs Direct Supply Agreement With Cord Blood Registry
GlobeNewswire - Wed Jan 08, 8:00AM CST
ThermoGenesis Corp. (Nasdaq:KOOL), a leading supplier of enabling technologies for the processing and storage of stem cells and other biological tissues, today announced the signing of a five-year agreement to supply Cord Blood Registry (CBR), the world's largest and most experienced newborn stem cell company, with ThermoGenesis' AutoXpress System (AXP) cord blood processing system and disposables. The AXP System is a proprietary family of automated devices with companion sterile blood processing disposables for harvesting cord blood stem cells in closed systems. Previously, ThermoGenesis supplied CBR the AXP System indirectly through its North American independent distributor.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Africa Tech Festival 2026: A Digital Turning Point

Updated Category News Views 96

Setting the Stage for Digital Advancement in Africa Come mid-November, Cape Town's gonna be buzzing with the clatter of tech titans and financial honchos making their annual pilgrimage to the Africa Tech Festival. This ain't just a conference shindig—with names like Naspers, MTN, Meta, and Amazon on the docket, it's a darn convention shaping the continent's future...

Continue Reading
Caregiving's Financial Impact on Women: Insights from Cinergy

Updated Category News Views 84

Women Caregivers Face Financial Crossroads When it comes down to it, caregiving is one heck of a responsibility, particularly for women. It's about the sacrifices they make, not just in time but in financial security, too. Step away from a job to care for someone, and it's a dicey game you're playing with future income. The Cost of Generosity: Financial Impacts Cindy...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 279

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 421

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Life Insurance: Evolving with Your Financial Journey

Updated Category News Views 32

Why Life Insurance Isn't Just a 'Set It and Forget It' Life insurance isn't some one-time deal you lock in and toss aside. Mike Newell, an insurance pro, highlights how life's shifts—whether in income, dependents, or debt—should drive tweaks to your coverage. As your life story unfolds, so too should the backbone of your financial security. Early Adulthood: Setting...

Continue Reading
Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 80

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
Peptide Tracker Refresh Unveils New Planning Features

Updated Category News Views 103

Peptide Tracker's Latest Updates: A Game Changer? I'll tell you what—if you're keeping tabs on your peptide intake like a seasoned gardener checks the soil, Peptide Tracker's fresh versions 3.2.0 and 3.3.0 might just be your new best mates. With the addition of washout scheduling and a robust six-month schedule preview, this isn't just another fancy tech update. It's...

Continue Reading
Pine Tree Bets Big on Tulsa Hills Shopping Center

Updated Category News Views 85

Pine Tree's Latest Move in Retail Real Estate Ya ever watch a company make a move so aligned with its playbook that it feels like a script straight outta the boardroom? That's Pine Tree with its recent snag of Tulsa Hills Shopping Center for a cool $108 million. This ain't just any retail spot; it's a bustling hub nestled within the posh outskirts of Jenks, Oklahoma....

Continue Reading
ISC2 Launches AI Security Academy for Cyber Pros

Updated Category News Views 59

AI-Driven Threats Demand Expert Attention Every corner of the tech world has been blabbering about AI, but when it comes to cybersecurity, it's a whole different beast entirely. ISC2—a nonprofit that I like to think of as the cyber wizards’ guild—just threw a lifeline to cybersecurity folks who are swimming in the deep end of AI. With their shiny new AI Security...

Continue Reading
Rock Tech Uncovers Major Lithium Discovery at Victory

Updated Category News Views 59

Rock Tech's Game-Changer at Victory Folks, we've got a shake-up in the lithium landscape over in Ontario, courtesy of Rock Tech Lithium Inc. They just unearthed something quite promising at their Victory Project: a spanking new spodumene-bearing pegmatite discovery. Now I know, if you're like me, you're thinking, 'What's the angle here?' Well, this isn't just another hole...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Future of Fly Play hf. Amid Takeover Talks

Updated Category News Views 224

Understanding the Recent Developments at Fly Play hf. Fly Play hf. is currently navigating through a significant phase in its operational journey. Amid potential takeover discussions, stakeholders are keenly interested in how such a move could reshape the airline's direction. As the aviation industry continues to evolve, Fly Play's adaptability and innovative strategies...

Continue Reading
AvePoint Aims for Dual Listing at Singapore Exchange

Updated Category News Views 275

AvePoint's Ambitious Step Towards Dual Listing AvePoint (Nasdaq: AVPT), renowned as a leader in data security, governance, and resilience, is taking a significant step forward by submitting an application to list its shares on the Singapore Exchange Securities Trading Limited (SGX-ST). This application is set against the backdrop of its existing presence on the Nasdaq...

Continue Reading
Kris Kehl Joins Planet Home Lending to Enhance Services

Updated Category News Views 140

Kris Kehl Joins Planet Home Lending Team Planet Home Lending, a prominent national mortgage lender, is excited to announce the addition of Kris Kehl as a Senior Mortgage Loan Officer in California. With over 22 years of extensive experience in the mortgage industry, Kehl brings a relationship-first approach that prioritizes accessibility, clear communication, and...

Continue Reading
The S&P 500: Understanding Future Market Return Challenges

Updated Category News Views 647

Understanding Future Returns for the S&P 500 Recently, there’s been a surge of interest regarding predictions for future returns of the S&P 500. With insights from financial giants like J.P. Morgan and Goldman Sachs indicating a significantly lower return forecast for the coming decade, it’s essential to delve deeper into these evaluations. The consistent message has...

Continue Reading
Investors Can Seize Winds of Change with enCore Energy

Updated Category News Views 183

Understanding the Opportunity with enCore Energy Corp. Investors are currently presented with a significant opportunity to engage in the ongoing developments at enCore Energy Corp. (NASDAQ: EU). The global landscape is rapidly changing, especially in the energy sector, and enCore is no exception. A class action has been filed on behalf of shareholders who purchased...

Continue Reading